- Home
- LRFC vs ALXO Comparison
LRFC vs ALXO Comparison
Compare LRFC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRFC
- ALXO
- Stock Information
- Founded
- LRFC 2013
- ALXO 2015
- Country
- LRFC United States
- ALXO United States
- Employees
- LRFC N/A
- ALXO N/A
- Industry
- LRFC Finance: Consumer Services
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- LRFC Finance
- ALXO Health Care
- Exchange
- LRFC Nasdaq
- ALXO Nasdaq
- Market Cap
- LRFC N/A
- ALXO 76.5M
- IPO Year
- LRFC 2013
- ALXO 2020
- Fundamental
- Price
- LRFC $21.56
- ALXO $0.60
- Analyst Decision
- LRFC
- ALXO Strong Buy
- Analyst Count
- LRFC 0
- ALXO 6
- Target Price
- LRFC N/A
- ALXO $4.14
- AVG Volume (30 Days)
- LRFC 5.5K
- ALXO 1.4M
- Earning Date
- LRFC 03-13-2025
- ALXO 03-06-2025
- Dividend Yield
- LRFC 6.57%
- ALXO N/A
- EPS Growth
- LRFC N/A
- ALXO N/A
- EPS
- LRFC N/A
- ALXO N/A
- Revenue
- LRFC $20,916,000.00
- ALXO N/A
- Revenue This Year
- LRFC N/A
- ALXO N/A
- Revenue Next Year
- LRFC N/A
- ALXO N/A
- P/E Ratio
- LRFC N/A
- ALXO N/A
- Revenue Growth
- LRFC 3.66
- ALXO N/A
- 52 Week Low
- LRFC $20.65
- ALXO $0.59
- 52 Week High
- LRFC $26.00
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- LRFC 30.40
- ALXO 31.52
- Support Level
- LRFC $21.70
- ALXO $0.65
- Resistance Level
- LRFC $22.36
- ALXO $0.72
- Average True Range (ATR)
- LRFC 0.50
- ALXO 0.07
- MACD
- LRFC -0.12
- ALXO -0.00
- Stochastic Oscillator
- LRFC 9.68
- ALXO 6.09
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.